Harvard Onconephrology Symposium 2026

Description

+ Include:  videos + file sub vtt +  pdf, size:  GB

+ Target Audience: Nephrologists, Transplant Nephrologists, Medical Oncologists, Hematologists Renal Pathologists, Cardio-Oncologists, Palliative Care Specialists, Hospitalists, and Internists

+ Sample video: contact me for sample video

+ Information:

Advance your onconephrology expertise by joining a dynamic, expert-led symposium designed to equip clinicians with up-to-date knowledge at the intersection of cancer and kidney care. Gain practical insights, emerging evidence, and multidisciplinary strategies to better diagnose, manage, and support the growing population of cancer patients facing complex renal conditions.

At least 1 out of every 10 cancer patients will experience acute kidney injury, and up to 25% will have chronic kidney disease. Cancer is a common global problem, and as cancer treatments evolve, nephrologists will be tasked with diagnosing and managing more complex cases within this cohort of patients. The 2026 Onconephrology Symposium will offer up to date information and insights from national and international experts in this constantly evolving subspecialty. The goal of this forum is to provide an opportunity for academicians and clinicians to have personal exchanges with experts in this steadily expanding subspecialty in order to enhance the clinical experience of our cancer patients. Topics covered will include an update on cancer therapies and renal impact, paraneoplastic glomerular disorders, thrombotic microangiopathy, and monoclonal disorders, to name a few. This symposium is intended for physicians, advanced practice providers, nurses, medical students, and other health care professionals in Hospital Medicine, Internal Medicine, Nephrology, Hematology, and Oncology.

Learning Objectives

• Diagnose and manage various forms of renal complications in patients with cancer.

• Learn to work in a multi-disciplinary group of providers to enhance the experience of our patients with cancer.

• Review cancer associated with glomerular disease, thrombotic microangiopathy, and monoclonal gammopathies with updates on latest diagnostics and management.

• Consider the role of kidney transplant in patients with cancer.

• Understand the landscape of cancer therapy including chemo, cellular, immune, and targeted therapy with update on reno-protective strategies.

Target Audience

This symposium is intended for physicians, advanced practice providers, nurses, medical students, and other health care professionals in Hospital Medicine, Internal Medicine, Nephrology, Hematology, and Oncology.

Who Should Participate: MDs and DOs.

Best for Nephrologists, Transplant Nephrologists, Medical Oncologists, Hematologists (Hematologic Oncologists / Blood and Marrow Transplant Specialists), Renal Pathologists, Cardio-Oncologists (Cardiologists), Palliative Care Specialists, Hospitalists, and Internists.

Topics

• Day 1: Thursday, September 17, 2026

  • Registration / Breakfast

  • Welcome From Course Directors

  • Welcome Message from a Pioneer

  • What Do BMT Docs Wish Nephrologists Knew about HSCT? (Includes Q&A)

  • Changing Diagnostic and Treatment Landscape of HSCT-TMA (Includes Q&A)

  • Cancer and Complementology (Includes Q&A)

  • Murine Models and Immune Therapy: What Can Mice Teach us About AIN? (Includes Q&A)

  • Break

  • Beyond Biopsy: Biomarkers and Treatments for ICI-AKI (Includes Q&A)

  • Lessons from Non-Renal Immune Related Adverse Events (Includes Q&A)

  • ICI-GN: A Conundrum (Includes Q&A)

  • Lunch Break / Poster Review

  • Toxicities of CAR-T and CAR-Treg

  • How Tumor Infiltrating Lymphocytes are Transforming Cancer Treatment

  • Q&A (Toxicities of CAR-T/CAR-Treg & Tumor Infiltrating Lymphocytes)

  • MAGnificent properties of Cisplatin: mitigating risk and managing AKI (Includes Q&A)

  • Target Trial Emulation in Onconephrology (Includes Q&A)

  • What’s the GFR!? Current Challenges in Cancer and Future Opportunities (Includes Q&A)

  • How Would I Dose Chemotherapy? A Case Review (Includes Q&A)

  • Break

  • Podocytes: An Innocent Bystander in Cancer (Includes Q&A)

  • Novel Treatments for Proteinuria and Hypertension: Is there a Role for Endothelin Inhibitors? (Includes Q&A)

  • SGLT2is: Are they a Miracle For Cancer- Associated Nephrotoxicity Too? (Includes Q&A)

  • Immune Complex Disease in Cancer: Future of Antigens (Includes Q&A)

  • Nephrocentric vs Nephrotolerant: When is it Safe to Rechallenge? (Includes Q&A)

  • Palliative Care in Onconephrology: Symptom Management and Decision Support (Includes Q&A)

  • Adjourn

• Day 2: Friday, September 18, 2026

  • Registration / Breakfast

  • The Other Renal Amyloids: It’s not ALL about AL Amyloid (Includes Q&A)

  • Pathophysiology of Cancer Therapy and Cardiotoxicity (Includes Q&A)

  • MGUS to Myeloma: Bench to the Bedside (Includes Q&A)

  • IKMG Update on MGRS: Future Associations and Mechanisms (Includes Q&A)

  • How do Immunoglobulins Cause Kidney Damage?

  • Q&A (IKMG Update on MGRS & Immunoglobulins Causing Kidney Damage)

  • Break

  • The Onconephrology Jeopardy Challenge (Includes Q&A)

  • How I Manage IgM Disease and Systemic Impact (Includes Q&A)

  • Light Chain Cast Nephropathy: Beyond Plex (CAR-T, Bispecific) (Includes Q&A)

  • The Clone That Stole the Gift: Transplant MGRS Case Review (Includes Q&A)

  • Post Kidney Transplant Lymphoproliferative Disorders: Perspectives from a Transplant Nephrologist (Includes Q&A)

  • The War Against Light Chains: A Case Debate (Includes Q&A)

  • Final Reflections / Poster Winners

  • Break